Table 1.
Odds ratios (OR) and 95% confidence intervals (CIs) for the association between frequency of aspirin and nonsteroidal anti-inflammatory drugs (NSAID) use and endometrial cancer risk, overall and by body mass index (BMI)
| Aspirina |
Non-aspirin NSAIDsa |
|||||
|---|---|---|---|---|---|---|
| Frequency of use | Cases | Controls | Cases | Controls | ||
| N (%) | N (%) | ORb (95% CI) | N (%) | N (%) | ORb (95% CI) | |
| Overall | ||||||
| <1/week | 3472 (70) | 6130 (65) | 1.00 (Ref) | 3443 (76) | 6878 (77) | 1.00 (Ref) |
| 1/week | 179 (4) | 428 (4) | 0.98 (0.80–1.20) | 124 (3) | 319 (3) | 0.80 (0.62–1.02) |
| 2–6/week | 450 (9) | 1114 (12) | 0.89 (0.78–1.02) | 446 (10) | 771 (9) | 0.93 (0.81–1.08) |
| Daily | 877 (17) | 1790 (19) | 0.96 (0.86–1.07) | 492 (11) | 989 (11) | 0.94 (0.82–1.08) |
| BMI < 25.0 kg/m2 | ||||||
| <1/week | 919 (71) | 2925 (68) | 1.00 (Ref) | 954 (81) | 3277 (80) | 1.00 (Ref) |
| 1/week | 52 (4) | 196 (5) | 1.04 (0.74–1.46) | 28 (2) | 159 (4) | 0.65 (0.42–1.01) |
| 2–6/week | 128 (10) | 495 (11) | 1.05 (0.84–1.32) | 90 (8) | 284 (7) | 1.10 (0.84–1.44) |
| Daily | 199 (15) | 710 (16) | 1.09 (0.90–1.31) | 100 (9) | 359 (9) | 1.19 (0.93–1.53) |
| BMI ≥ 25.0 kg/m2 | ||||||
| <1/week | 2466 (69) | 3108 (62) | 1.00 (Ref) | 2421 (75) | 3493 (74) | 1.00 (Ref) |
| 1/week | 126 (3) | 224 (4) | 0.93 (0.72–1.20) | 92 (3) | 153 (3) | 0.88 (0.65–1.19) |
| 2–6/week | 312 (9) | 600 (12) | 0.81 (0.68–0.96) | 342 (11) | 477 (10) | 0.87 (0.73–1.04) |
| Daily | 672 (19) | 1066 (21) | 0.91 (0.80–1.03) | 384 (12) | 621 (13) | 0.85 (0.73–1.00) |
| P-trend 0.02 | ||||||
a
Includes the Australian National Endometrial Cancer Study (ANECS), Connecticut Endometrial Cancer Study (CONN), FHCRC, PEDS (aspirin only), Iowa Women’s Health Study (IOWA), NIH and Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO).
b
Adjusted for age at diagnosis/interview (continuous), parity (continuous), BMI (kg/m2, continuous) and oral contraceptive use (ever/never), highest level of education and smoking.